Compare Delta Air Lines, Inc. (DAL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs DexCom, Inc. — how do they compare? Delta Air Lines, Inc. trades at $83.15 (market cap $54.56B), while DexCom, Inc. trades at $84.02 (market cap $31.81B). The key difference: Delta Air Lines, Inc. is the larger of the two by market cap, and Delta Air Lines, Inc. pays a 1.04% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and DexCom, Inc. for 62 Days on average.
| DAL | DXCM | |
|---|---|---|
Market Cap | $54.56B | $31.81B |
Volume | 6,532,736 | 2,861,821 |
Sector | Industrials | Health |
52-Week High | $93.66 | $92.34 |
52-Week Low | $55.65 | $54.84 |
Typical Hold Time | 97 Days | 62 Days |
Enterprise Value | $69.88B | $31.26B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.14, down 1.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. DAL maintains solid profitability with 5.78% net margin and 20.12% ROE, while trading at attractive valuations with P/E of 13.76 and P/S of 0.8. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's internet service over Starlink.
DAL presents a compelling value opportunity with strong analyst support (82% buy ratings) and 26% upside to consensus target of $103.36. However, near-term risks include fuel cost volatility, competitive threats to premium customers, and execution challenges. The improving cash flow trend with $1.08B net cash generation in 2025 supports dividend sustainability and operational flexibility.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
